Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Moderna shares plunge on plans to cut $1.1 billion in costs, launch 10 new products by 2027
Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.
Moderna lays out plan to slice research and development spending
Shares of Moderna tumbled early Thursday after the vaccine developer said it was cutting research and development spending and pushed back its time frame for breaking even.
Moderna touts research progress as it cuts R&D spending by $1.1 billion
After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.
Moderna: Cutting Costs At Just The Worst Time
Moderna shares have dropped by over -41.67% since I last covered them over the summer. See why I continue to rate MRNA stock a strong sell.
Moderna Stock Drops on Plans To Cut $1.1B in R&D Costs
Moderna shares fell Thursday morning as the COVID vaccine maker said it plans to cut R&D spending by $1.1 billion over the next three years.
Moderna to Cut Research, Development Spending, Prioritize New Product Approvals
Moderna (MRNA) said Thursday it plans to cut back on its research and development spending as the company looks to save costs and prioritize the launch of new products already in the pipeline. The drugmaker expects to reduce its annual R&D budget to a range between $3.
7d
on MSN
After Moderna's Shocking News, Is the Stock a Buy or a Sell?
Now, let's get back to our question. Is the stock a buy or a sell? This depends a lot on your own particular investment ...
6d
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Investor's Business Daily on MSN
5d
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.
3d
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
1d
Down 13% in 1 Day, Is Moderna Stock in Trouble?
Moderna 's (NASDAQ: MRNA) stock fell by 13% on Sept. 12 upon the announcement of extensive cost cuts that would affect a handful of its pipeline programs and terminate a few others. Now, management is ...
5d
Moderna’s ‘Off-the-Shelf’ Cancer Vaccine Shows Promise in Early Human Trial Data
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
2d
Behind the Scenes of Moderna's Latest Options Trends
In terms of liquidity and interest, the mean open interest for Moderna options trades today is 1286.5 with a total volume of ...
9d
Moderna forecasts lower sales next year, shares near four-year low
Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key ...
1d
Moderna: Still Bullish View
Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
MRNA
Jim Cramer
COVID
Spikevax
Period
Feedback